Global Advanced Drug Delivery CDMO Market Size is predicted to show a 5.0% CAGR during the forecast period for 2025-2034.
The pharmaceutical sector greatly benefits from a Contract Development and Manufacturing Organisation (CDMO) specialising in cutting-edge drug delivery technologies. These CDMOs offer services for creating, formulating, and developing drug delivery systems beyond conventional oral tablets or capsules. Modern medication delivery systems have arisen as a quick and precise way to get the drug to the right place. These systems have several advantages over conventional systems, including the focused and regulated delivery of novel molecules to target areas, consistent drug absorption, reduced frequency of dosing, decreased production of hazardous metabolites, and lower variability in systemic drug concentrations.
The need for advanced drug delivery CDMOs has increased as a result of improved drug performance and superior results brought about by advanced drug delivery systems. However, the Advanced Drug Delivery Contract Development and Manufacturing Organisation (CDMO) market was significantly impacted by the COVID-19 pandemic, which had a wide-ranging effect on the sector. The pandemic affected the availability of raw materials and parts needed for medicine delivery systems by upsetting global supply chains. For several CDMOs, this resulted in manufacturing difficulties and delivery delays.
Competitive Landscape
Some Major Key Players in the Advanced Drug Delivery CDMO Market are:
- Catalent, Inc.
- Lonza Group AG
- Kindeva Drug Delivery
- MedPharm (merged with Tergus Pharma)
- WuXi AppTec
- Hovione
- Piramal Pharma Solutions
- CordenPharma International
- Divi’s Laboratories
- Lifecore Biomedical
- Recipharm AB
- Syngene International
- Thermo Fisher Scientific (Patheon)
- Aenova Group
- Cellipoint Bioservices
- Evonik Health Care
- SHL Medical
- Lubrizol Life Science
- Acino International AG
- Pharmathen
- Phillips-Medisize (A Molex Company)
- Others
Market Segmentation:
The advanced drug delivery CDMO market is segmented on the basis of services which is segmented as service type, technology, dosage form, application and end-user. Based on the service type, the market segmented into formulation development, process development and scale-up, analytical and testing services, manufacturing services, packaging and, device development, regulatory support. Based on the technology, the market segmented into targeted drug delivery systems, controlled/sustained-release technologies, injectable delivery platforms, pulmonary & nasal delivery systems, transdermal & microneedle delivery, mucosal delivery methods, implantable delivery devices, 3d-printed drug delivery. Based on the dosage form, the market segmented into injectables, oral solids, topical & transdermal, implantables & ocular. Based on the application, the market segmented into oncology, infectious diseases, neurological disorders, cardiovascular diseases, other. Based on the end-user, the market segmented into clinical, commercial.
The Segment, Analytical and Testing Services, Accounted As A Major Contributor In The Advanced Drug Delivery CDMO Market.
The analytical and testing services category is expected to hold a major share in the global Advanced Drug Delivery CDMO Market in 2025. Advanced drug delivery technologies such as liposomes, nanoparticles, implants, and long-acting injectables require sophisticated testing to ensure their performance, safety, and stability. These systems often exhibit complex release profiles, encapsulation efficiencies, and bioavailability parameters that must be validated using high-precision analytical methods. Analytical services are essential at every stage of the drug development lifecycle, from preformulation and clinical trials to regulatory submission and post-marketing surveillance. As a result, the Analytical and Testing Services segment holds the largest share in the advanced drug delivery CDMO market, as it plays a critical role in ensuring the quality, safety, regulatory compliance, and functional performance of increasingly complex drug delivery systems.
In The Region, The North American Advanced Drug Delivery CDMO Market Holds A Significant Revenue Share.
The North America Advanced Drug Delivery CDMO Market is expected to record the maximum market share in terms of revenue in the near future. The region's long-standing CDMO presence distinguishes the market in North America. The region is heavily invested in researching and developing biological medications, gene treatments, and other specialized pharmaceuticals. These complex compounds frequently necessitate specialized drug delivery devices, which drives demand for CDMO services. Along with this element, expanding partnerships between pharmaceutical firms and CDMOs providing a wide range of services are to blame for the region's leading market share globally. Due to the region's highly qualified workforce and low manufacturing and R&D costs, the Asia Pacific market is estimated to grow significantly over the course of the forecast period.
Recent Developments:
- In July 2023, SHL Medical said it had bought LCA Automation AG, a Swiss company that makes innovative automation solutions. The purchase was SHL Medical's answer to the growing need for drug delivery options in the market. It also helped its manufacturing operations around the world, especially the new factory that will open in Zug, Switzerland.
- In March 2023, Evonik has solidified its prominent position in drug delivery for RNA treatments by initiating the construction process for a new pharmaceutical lipids plant in the United States. The newly established facility was anticipated to ensure the industry's uninterrupted availability of essential excipients required for mRNA vaccines and other nucleic acid therapeutics. The commencement of plant operations was planned for the year 2025.
Advanced Drug Delivery CDMO Market Report Scope :
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD XXX Mn |
|
Revenue Forecast In 2034 |
USD XXX Mn |
|
Growth Rate CAGR |
CAGR of 5.0% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Service Type, Technology, Dosage Form, Application, End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; South East Asia |
|
Competitive Landscape |
Catalent, Inc., Lonza Group AG, Kindeva Drug Delivery, MedPharm (merged with Tergus Pharma), WuXi AppTec, Hovione, Piramal Pharma Solutions, CordenPharma International, Divi’s Laboratories, Lifecore Biomedical, Recipharm AB, Syngene International, Thermo Fisher Scientific (Patheon), Aenova Group, Cellipoint Bioservices, Evonik Health Care, SHL Medical, Lubrizol Life Science, Acino International AG, Pharmathen, Phillips-Medisize (A Molex Company), Others |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
